Skip to main content

Table 3 Predictors of remission at 52 weeks of adalimumab treatment (multivariate analysis)

From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan

Factor Odds ratio (95 % CI) P value
CDAI at baseline 0.993 (0.985–1.000) 0.0577
Colonic type 0.207 (0.035–1.230) 0.0833
  1. CI confidence interval, CDAI Crohn’s Disease Activity Index